New combo therapy aims to tackle lung cancer brain metastases
NCT ID NCT07413952
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new targeted cancer pill called limertinib combined with brain radiation as a first treatment for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. The goal is to see if the combination can better control the brain tumors. The trial plans to enroll 45 participants and is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Limertinib (a targeted cancer pill) plus radiotherapy (focused radiation to the brain)
What this could lead to
If successful, this combination could offer a more effective first-line option for controlling brain metastases in EGFR-mutant lung cancer, potentially improving how long the cancer stays under control in the brain.
What could go wrong
This is a small, early-phase (Phase II) study with only 45 participants and no comparison group, so results may not apply broadly. The combination may also increase side effects from both treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••